Indiana University/Melvin and Bren Simon Cancer Center

Clinical research site in Indianapolis, Indiana · 1001 W 10TH ST # M200, WISHARD HOSPITAL, INDIANAPOLIS, IN 46202-2859 · (317) 630-6857

Part of Indiana University

As of July 2026, 54 paid clinical trials are recruiting at Indiana University/Melvin and Bren Simon Cancer Center in Indianapolis, Indiana. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 and Stage IV Lung Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Indiana University/Melvin and Bren Simon Cancer Center (54)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

62 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

for Non-Muscle Invasive Bladder Neoplasms

13 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07309445·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

for Nausea

20 locations incl. Greenbrae

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07169851·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

9 locations incl. Orange

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

18 locations incl. Scottsdale

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Methylprednisolone in People Having Liver Surgery

for Hepatectomy

19 locations incl. Chicago

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07507643·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

585 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

466 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

309 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

for Plasma Cell Myeloma

228 locations incl. Phoenix

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT04566328·Phase 3·Recruiting·Listed Sep 2020

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

387 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

449 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

950 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019

Apply to this trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

405 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for Plasma Cell Myeloma

389 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: All ages

Code: NCT05561387·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

328 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

336 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting·Listed Jan 2020

Apply to this trial

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

for Anaplastic Large Cell Lymphoma, ALK-Negative

137 locations incl. Birmingham

Sponsor: Eastern Cooperative Oncology Group

Sex: All·Age: 18 - 75

Code: NCT06724237·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for Lung Non-Small Cell Carcinoma

263 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06498635·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

223 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

192 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

250 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

241 locations incl. DeKalb

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

209 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for Endometrial Adenocarcinoma

126 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05112601·Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

for Breast Cancer

637 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: All·Age: 18 - 100

Code: NCT05896189·Recruiting·Listed Jun 2023

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

381 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for Recurrent Non-Muscle Invasive Bladder Carcinoma

58 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT07000084·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

241 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18 Minutes+

Code: NCT06031688·Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

243 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

645 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Showing the 40 most relevant of 54 recruiting trials at this site. Browse all with filters →

More research sites in Indianapolis

Indiana University (100 trials)
Riley Hospital for Children (67 trials)
Indiana University School of Medicine (54 trials)
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (27 trials)
Indiana University Health (22 trials)
Indiana University Health University Hospital (20 trials)
Saint Catherine Hospital (20 trials)
Community Health Network (19 trials)
Indiana University Hospital (17 trials)
IU Health Methodist Hospital (15 trials)

Explore more

Paid clinical trials in Indianapolis, IN · Indiana clinical trials